February 27, 2017
Midatech borrows £6 million
Midatech has borrowed £6 million from Silicn Valley Bank to add to the placing of the shares it made in October last year.
Pharmaceuticals, Biotechnology and Life Sciences
Category: Approval
February 27, 2017
Sanofi teams up with Lonza to invest €270 million in a mammalian cell culture site in Switzerland
Sanofi and Lonza will invest €270 million (CHF 290 million) in a mammalian cell culture site for monoclonal antibody production in Swiss town of Visp, planned for opening in 2020.
February 27, 2017
Global Market Insights says clinical trial management system market worth $2 billion by 2024
Growing prevalence of chronic diseases, surge in clinical trials outsourcing, rising R&D cost and favorable government initiatives will drive global clinical trial management system market size, according to a report by Global Market Insights.
February 24, 2017
Novartis makes first step in making Tafinlar + Mekinist available for certain NSCLC patients
Novartis could get first targeted treatment for patients with BRAF non-small cell lung cancer if European Medicines Agency (EMA) approves Tafinlar+Mikinist combination.
February 24, 2017
Oncology focused drugmaker Xynomic Pharmaceuticals secures Abexinostat global rights
Oncology drug research and development company Xynomic Pharmaceuticals has acquired exclusive worldwide rights to develop a novel HDAC inhibitor targeting hematological and solid tumors, Abexinostat.
February 24, 2017
OncoGenex has enough money for next year as it waits a mid-year merger with Achieve Life Sciences
Vancouver-based drugmaker OncoGenex didn’t make any revenues in the fourth quarter 2016, and it finished the year with a net loss for the fourth quarter and year ended December 31, 2016 of $5.8 million and $20.1 million, respectively.
February 23, 2017
China updates key drug list in boost for Big Pharma
China has updated list of medicines covered by basic medical insurance schemes, a long-awaited fillip for drugmakers in the world’s second-largest drug market where many new drugs have been kept out of patients’ reach because of high costs.
February 23, 2017
Oxford Pharmascience’s OXPzero Ibuprofen can act faster in a human study compared to its bioequivalent
Oxford Pharmascience’s interim PK study showed that the technolology modifications can not only make OXPzero Ibuprofen bioequivalent to OTC Nurofen, but also potentially faster acting, the drugmaker said in an update on OXPzero Ibuprofen clinical program, for which on January 17, it kicked off dosing healthy patients in the first phase of the study.
February 23, 2017
Novartis’s cancer drug wins FDA’s sNDA, priority review and breakthrough therapy designation
US Food and Drug Administration (FDA) has accepted Novartis’s supplemental New Drug Application (sNDA) for filing, and granted Priority Review for the expanded use of Zykadia (ceritinib) as a first-line treatment for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test.
February 23, 2017
PureTech Health names ex SVP at GlaxoSmithKline as Chief Medical Officer, aims for launching new drugs
PureTech Health has named new Chief Medical Officer to see all clinical operations across its pipeline and will focus on pushing chances that have most potential for patients.